ABOUT ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS

In Phase A, members will receive diverse doses and schedules of oral ABBV-744 tablet to identify safe dosing program. Additional participants will be enrolled within the determined monotherapy dosign routine. In Segment B, contributors will acquire oral ruxolitinib and ABBV-744 are going to be supplied as "incorporate-on" therapy. In Phase C, membe